0000950170-24-056292.txt : 20240509 0000950170-24-056292.hdr.sgml : 20240509 20240509080013 ACCESSION NUMBER: 0000950170-24-056292 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240509 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NewAmsterdam Pharma Co N.V. CENTRAL INDEX KEY: 0001936258 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41562 FILM NUMBER: 24928661 BUSINESS ADDRESS: STREET 1: GOOIMEER 2-35 CITY: NARRDEN STATE: P7 ZIP: 1411 DC BUSINESS PHONE: 35 206 2971 MAIL ADDRESS: STREET 1: GOOIMEER 2-35 CITY: NARRDEN STATE: P7 ZIP: 1411 DC FORMER COMPANY: FORMER CONFORMED NAME: NewAmsterdam Pharma Co B.V. DATE OF NAME CHANGE: 20220701 8-K 1 nams-20240509.htm 8-K 8-K
false000193625800-00000000001936258us-gaap:CommonStockMember2024-05-092024-05-0900019362582024-05-092024-05-090001936258us-gaap:WarrantMember2024-05-092024-05-09

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 09, 2024

 

 

NewAmsterdam Pharma Company N.V.

(Exact name of Registrant as Specified in Its Charter)

 

 

The Netherlands

001-41562

N/A

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

Goomieer 2-35

 

Naarden

 

 

The Netherlands

 

1411 DC

(Address of Principal Executive Offices)

 

(Zip Code)

 

+31 (0) 35 206 2971

 

(Registrant’s Telephone Number, Including Area Code)

 

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Ordinary shares, nominal value €0.12 per share

 

NAMS

 

The Nasdaq Stock Market LLC

Warrants to purchase ordinary shares

 

NAMSW

 

The Nasdaq Stock Market LLC

 

☒

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On May 9, 2024, NewAmsterdam Pharma Company N.V. (the “Company”) issued a press release announcing corporate updates and its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 hereto.

 

In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit No.

 

Description

 

 

99.1

 

NewAmsterdam Pharma Company N.V. Press Release, dated May 9, 2024

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

NewAmsterdam Pharma Company N.V.

 

 

 

 

Date:

May 9, 2024

By:

/s/ Michael Davidson

 

 

Name:

Michael Davidson, M.D.

 

 

Title:

Chief Executive Officer

 

 

 EX-99.1 2 nams-ex99_1.htm EX-99.1 EX-99.1

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

 

-- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT--

-- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 --

 

-- Dosed first patients in TANDEM, pivotal Phase 3 trial evaluating fixed-dose combination of obicetrapib and ezetimibe; topline data expected in 1Q 2025 --

 

-- Company to host R&D event on May 16, 2024, beginning at 9:00 a.m. ET in New York City –

 

-- Strong financial position; ending the quarter with $481.1 million in cash --

 

Naarden, the Netherlands and Miami, USA; May 9, 2024 – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced corporate updates and financial results for the quarter ended March 31, 2024.

 

“Recent months were marked by important milestones across our organization as we execute our multi-pronged clinical development strategy for obicetrapib and begin to prepare for a global launch,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam. “We recently completed enrollment in PREVAIL, our cardiovascular outcomes trial ("CVOT”), and initiated TANDEM, a pivotal Phase 3 trial evaluating a fixed-dose combination of obicetrapib and ezetimibe. These trials, alongside BROOKLYN and BROADWAY, are expected to provide important insights into obicetrapib’s ability to potentially improve upon the existing standard of care, by helping patients achieve their target LDL-C goals and, ultimately, avoid catastrophic outcomes. We are grateful to patients and physicians globally for their partnership, and we look forward to reporting pivotal data, beginning with topline results from BROOKLYN and BROADWAY in the third and fourth quarters of this year, respectively.”

 

Dr. Davidson continued, “In parallel, we are working diligently to lay the foundation for a future global launch of obicetrapib, if approved. We believe that the market opportunity for obicetrapib is substantial; millions of people are living with hypercholesterolemia and many of those with atherosclerotic cardiovascular disease (“ASCVD”) or heterozygous familial hypercholesterolemia (“HeFH”) are not achieving LDL-C targets, despite the availability of statin therapies and PCSK9 inhibitors. We look forward to sharing additional details on our pre-launch activities and commercial strategy at our R&D Day on May 16th and, if our Phase 3 program is successful and regulatory approval is received, to delivering obicetrapib to improve health outcomes for CVD patients worldwide.”

 

Clinical Development Updates:

 

NewAmsterdam is developing obicetrapib, an oral, low-dose and once-daily cholesteryl ester transfer protein (“CETP”) inhibitor, as the preferred LDL-C lowering therapy to be used in patients at risk of CVD for whom existing therapies are not sufficiently effective or well-tolerated.

•
In March 2024, NewAmsterdam announced the initiation of, and the dosing of the first patient in, TANDEM, a pivotal Phase 3 clinical trial to evaluate a fixed-dose combination of obicetrapib and ezetimibe in adult patients with HeFH and/or ASCVD or multiple risk factors for ASCVD, whose LDL-C is not adequately controlled despite being on maximally tolerated lipid-modifying therapies.
•
In April 2024, NewAmsterdam announced that it has met the enrollment target for the pivotal Phase 3 PREVAIL CVOT evaluating obicetrapib in adult patients with a history of ASCVD, whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. Driven by strong patient and physician interest globally, NewAmsterdam extended enrollment to the end of April and randomized over 9,500 patients.
•
Also in April 2024, at the 2024 American College of Cardiology Congress, NewAmsterdam presented additional data from the Phase 2 ROSE2 clinical trial, which evaluated the impact of obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy on multiple lipid biomarkers, including LDL particle number and small dense LDL-C.

 

Corporate Updates

 

•
In January 2024, NewAmsterdam appointed William H. Lewis, J.D., M.B.A as Chair of its Board of Directors. Mr. Lewis has more than 30 years of executive experience in the pharmaceutical and finance industries both in the U.S. and internationally and has been widely recognized for his commitment to a patient-first approach to drug discovery, development, and commercialization.
•
In February 2024, NewAmsterdam completed an upsized public offering of 5,871,909 ordinary shares and 4,736,841 pre-funded warrants, generating net proceeds of $190.0 million after deducting underwriting discounts and commissions and offering expenses payable by the Company. NewAmsterdam intends to use the additional capital to support the continued development and ongoing commercial readiness of obicetrapib. The offering attracted several new and existing investors.
•
In April 2024, NewAmsterdam appointed Juliette Audet as Chief Business Officer. Simultaneous with this announcement, Ms. Audet resigned from the Company’s Board of Directors. Ms. Audet is a seasoned life sciences executive with extensive pharmaceutical business development, finance and operational expertise. In her prior role as a Partner at Forbion, she was part of the team that built NewAmsterdam and she played a key role in out licensing obicetrapib, setting up operations and recruiting NewAmsterdam’s management team.

 

Upcoming Potential Milestones

 

NewAmsterdam currently expects to achieve the following upcoming milestones:

•
Announce topline data from the Phase 3 BROOKLYN trial for obicetrapib monotherapy in the third quarter of 2024. BROOKLYN is evaluating obicetrapib in patients with HeFH, whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.
•
Announce topline data from the Phase 3 BROADWAY trial for obicetrapib monotherapy in the fourth quarter of 2024. BROADWAY is evaluating obicetrapib in adult patients with HeFH and/or established ASCVD, whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.
•
Announce topline data from the Phase 3 TANDEM trial evaluating a fixed-dose combination of obicetrapib and ezetimibe in first quarter of 2025.

 

Upcoming Investor Events

 

NewAmsterdam management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14 at 4:35 p.m. ET in New York City.

 

Additionally, NewAmsterdam will host an R&D Day event on Thursday, May 16, 2024, beginning at 9:00 a.m. ET in New York City. The event will feature a panel discussion and presentations from management to discuss obicetrapib’s clinical development path, the Company’s commercial readiness and strategy, and the cardiovascular disease landscape and opportunities for innovative new products.

 

Live webcasts of both events will be available through the investor relations section of the NewAmsterdam website at ir.newamsterdampharma.com. Following the live webcasts, archived replays will be available on the Company’s website.

 

First Quarter Financial Results

 

·
Cash Position: As of March 31, 2024, NewAmsterdam recorded cash of $481.1 million, compared to $340.5
million as of December 31, 2023. The increase in cash is primarily driven by the proceeds of the follow-on offering and warrant exercises partially offset by cash outflows related to research and development costs as the Company continues development of obicetrapib and increased spending on selling, general and administrative expenses to support the Company's growing organization.
·
Revenue: NewAmsterdam recognized $1.4 million in revenue for the quarter ended March 31, 2024, compared to $8.6 million in the same period in 2023. This decrease was primarily due to the recognition of license revenue related to a clinical development milestone in the quarter ended March 31, 2023 while no clinical development milestones were achieved in the same period in 2024.
·
Research and Development (“R&D”) Expenses: R&D expenses were $42.4 million in the quarter ended March 31, 2024, compared to $40.4 million for the same period in 2023. This increase was primarily due to an increase in clinical expenses related to the Company's ongoing Phase 3 clinical trials, partially offset by a decrease in manufacturing costs.
·
Selling, General and Administrative (“SG&A”) Expenses: SG&A expenses were $14.5 million in the quarter ended March 31, 2024, compared to $8.1 million for the same period in 2023. This increase was primarily due to an increase in personnel costs related to expansion of the team to support the growth of the organization and investments in capabilities to support the Company's planned commercial launch of obicetrapib, if approved.
·
Net loss: Net loss for the quarter ended March 31, 2024 was $93.8 million, or $1.06 per diluted share, compared to net loss of $42.0 million, or $0.51 per diluted share, for the same period in 2023.

 

About Obicetrapib

 

Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company is conducting two Phase 3 pivotal trials, BROADWAY and BROOKLYN, to evaluate obicetrapib as a monotherapy used as an adjunct to maximally tolerated lipid-lowering therapies to provide additional LDL-lowering for CVD patients and TANDEM, to evaluate obicetrapib and ezetimibe as a fixed-dose combination. The Company began enrolling patients in BROADWAY in January 2022, in BROOKLYN in July 2022, and in TANDEM in March 2024; completing enrollment of BROOKLYN in April 2023 and BROADWAY in July 2023. The Company also commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and non-elective coronary revascularization. NewAmsterdam completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients.

 

About NewAmsterdam

 

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

 

Forward-Looking Statements

 

Certain statements included in this document that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,”

“future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the Company’s business and strategic plans, the Company’s commercial opportunity, the therapeutic and curative potential of the Company’s product candidate, the Company’s clinical trials and the timing for enrolling patients, the timing and forums for announcing data, the achievement and timing of regulatory approvals, and plans for commercialization. These statements are based on various assumptions, whether or not identified in this document, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to the approval of the Company’s product candidate and the timing of expected regulatory and business milestones, including potential commercialization; ability to negotiate definitive contractual arrangements with potential customers; the impact of competitive product candidates; ability to obtain sufficient supply of materials; global economic and political conditions, including the Russia-Ukraine and Israel-Hamas conflict; the effects of competition on the Company’s future business; and those factors described in the Company’s public filings with the Securities Exchange Commission. Additional risks related to the Company’s business include, but are not limited to: uncertainty regarding outcomes of the Company’s ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidate; risks associated with the Company’s efforts to commercialize a product candidate; the Company’s ability to negotiate and enter into definitive agreements on favorable terms, if at all; the impact of competing product candidates on the Company’s business; intellectual property related claims; the Company’s ability to attract and retain qualified personnel; ability to continue to source the raw materials for its product candidate. If any of these risks materialize or the Company’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company’s expectations, plans, or forecasts of future events and views as of the date of this document and are qualified in their entirety by reference to the cautionary statements herein. The Company anticipates that subsequent events and developments may cause the Company’s assessments to change. These forward-looking statements should not be relied upon as representing the Company’s assessment as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither the Company nor any of its affiliates undertakes any obligation to update these forward-looking statements, except as may be required by law.

 

Company Contact

Matthew Philippe

P: 1-917-882-7512

matthew.philippe@newamsterdampharma.com

 

Media Contact

Spectrum Science on behalf of NewAmsterdam

Jen Gordon

P: 1-202-957-7795

jgordon@spectrumscience.com

 

Investor Contact

Stern Investor Relations on behalf of NewAmsterdam

Hannah Deresiewicz

P: 1-212-362-1200

hannah.deresiewicz@sternir.com

 

Financial Tables

 

NewAmsterdam Pharma Company N.V.

Condensed Consolidated Balance Sheets

(Unaudited)

 

March 31,
2024

 

 

December 31,
2023

 

(In thousands of USD)

 

 

 

 

 

Assets

 

Current assets:

 

 

 

 

 

Cash

 

481,147

 

 

 

340,450

 

Prepayments and other receivables

 

6,675

 

 

 

6,341

 

Total current assets

 

487,822

 

 

 

346,791

 

Property, plant and equipment, net

 

101

 

 

 

46

 

Operating right of use asset

 

38

 

 

 

55

 

Intangible assets

 

486

 

 

 

170

 

Long term prepaid expenses

 

16

 

 

 

35

 

Total assets

 

488,463

 

 

 

347,097

 

Liabilities and Shareholders' Equity

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Accounts payable

 

8,536

 

 

 

16,923

 

Accrued expenses and other current liabilities

 

9,970

 

 

 

11,398

 

Deferred revenue, current

 

8,116

 

 

 

8,942

 

Lease liability, current

 

43

 

 

 

60

 

Derivative warrant liabilities

 

33,061

 

 

 

12,574

 

Total current liabilities

 

59,726

 

 

 

49,897

 

Deferred revenue, net of current portion

 

444

 

 

 

1,019

 

Derivative earnout liability

 

16,490

 

 

 

7,788

 

Total liabilities

 

76,660

 

 

 

58,704

 

Commitments and contingencies (Note 10)

 

 

 

 

 

Shareholders' Equity (deficit):

 

 

 

 

 

Ordinary shares, €0.12 par value; 400,000,000 shares authorized; 89,720,836 and 82,469,768 shares issued and outstanding as at March 31, 2024 and December 31, 2023, respectively

 

11,113

 

 

 

10,173

 

Additional paid-in capital

 

807,008

 

 

 

590,771

 

Accumulated loss

 

(410,740

)

 

 

(316,973

)

Accumulated other comprehensive income (loss)

 

4,422

 

 

 

4,422

 

Total shareholders' equity

 

411,803

 

 

 

288,393

 

Total liabilities and shareholders' equity (deficit)

 

488,463

 

 

 

347,097

 

 

 

 

NewAmsterdam Pharma Company N.V.

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(Unaudited)

 

For the three months ended March 31,

 

 

2024

 

 

2023

 

(In thousands of USD, except per share amounts)

 

 

 

 

 

Revenue

 

1,401

 

 

 

8,629

 

Operating expenses:

 

 

 

 

 

Research and development expenses

 

42,430

 

 

 

40,420

 

Selling, general and administrative expenses

 

14,453

 

 

 

8,062

 

Total operating expenses

 

56,883

 

 

 

48,482

 

Operating loss

 

(55,482

)

 

 

(39,853

)

Other income (expense):

 

 

 

 

 

Interest income

 

3,083

 

 

 

943

 

Fair value change – earnout and warrants

 

(38,950

)

 

 

(6,175

)

Foreign exchange gains/(losses)

 

(2,418

)

 

 

3,067

 

Loss before tax

 

(93,767

)

 

 

(42,018

)

Income tax expense

 

—

 

 

 

—

 

Loss and comprehensive loss for the period

 

(93,767

)

 

 

(42,018

)

Net loss per ordinary share

 

 

 

 

 

Basic and diluted

$

(1.06

)

 

$

(0.51

)

 

 

 

NewAmsterdam Pharma Company N.V.

Condensed Consolidated Statements of Shareholders' Equity (Deficit)

(Unaudited)

(In thousands of USD, except share amounts)

Shares

 

 

Amount

 

 

Additional Paid-In Capital

 

 

Accumulated Loss

 

 

Cumulative Translation Adjustments

 

 

Total Shareholders' Equity

 

Balance at December 31, 2022

 

81,559,780

 

 

 

10,055

 

 

 

555,625

 

 

 

(140,036

)

 

 

4,422

 

 

 

430,066

 

Exercise of warrants

 

208,032

 

 

 

27

 

 

 

2,671

 

 

 

—

 

 

 

—

 

 

 

2,698

 

Share-based compensation

 

—

 

 

 

—

 

 

 

7,663

 

 

 

—

 

 

 

—

 

 

 

7,663

 

Total loss and comprehensive loss for the period

 

—

 

 

 

—

 

 

 

—

 

 

 

(42,018

)

 

 

—

 

 

 

(42,018

)

As at March 31, 2023

 

81,767,812

 

 

 

10,082

 

 

 

565,959

 

 

 

(182,054

)

 

 

4,422

 

 

 

398,409

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2023

 

82,469,768

 

 

 

10,173

 

 

 

590,771

 

 

 

(316,973

)

 

 

4,422

 

 

 

288,393

 

Issuance of Ordinary Shares and Pre-Funded Warrants, net of issuance costs

 

5,871,909

 

 

 

759

 

 

 

189,207

 

 

 

—

 

 

 

—

 

 

 

189,966

 

Exercise of warrants

 

926,698

 

 

 

121

 

 

 

19,674

 

 

 

—

 

 

 

—

 

 

 

19,795

 

Exercise of stock options

 

452,461

 

 

 

60

 

 

 

(609

)

 

 

—

 

 

 

—

 

 

 

(549

)

Share-based compensation

 

—

 

 

 

—

 

 

 

7,965

 

 

 

—

 

 

 

—

 

 

 

7,965

 

Total loss and comprehensive loss for the period

 

—

 

 

 

—

 

 

 

—

 

 

 

(93,767

)

 

 

—

 

 

 

(93,767

)

As at March 31, 2024

 

89,720,836

 

 

 

11,113

 

 

 

807,008

 

 

 

(410,740

)

 

 

4,422

 

 

 

411,803

 


 

 

 

 

NewAmsterdam Pharma Company N.V.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

For the three months ended March 31,

2024

2023

(In thousands of USD)

Operating activities:

Loss for the period

(93,767

)

(42,018

)

Non-cash adjustments to reconcile loss before tax to net cash flows:

Depreciation and amortization

15

9

Non-cash rent expense

1

2

Fair value change - derivative earnout and warrants

38,950

6,175

Foreign exchange (gains)/losses

2,418

(3,067

)

Share-based compensation

7,918

7,616

Changes in working capital:

Changes in prepayments (current and non-current) and other receivables

956

(1,413

)

Changes in accounts payable

(8,311

)

(2,920

)

Changes in accrued expenses and other current liabilities

(1,381

)

6,997

Changes in deferred revenue

(1,401

)

(3,244

)

Net cash (used in)/provided by operating activities

(54,602

)

(31,863

)

Investing activities:

Purchase of property, plant and equipment, including internal use software

(385

)

(7

)

Net cash used in investing activities

(385

)

(7

)

Financing activities:

Proceeds from offering of ordinary shares and pre-funded warrants

190,481

—

Transaction costs on issue of Ordinary Shares and Pre-Funded Warrants

(515

)

—

Proceeds from exercise of warrants

8,763

2,392

Proceeds from exercise of options

440

—

Payment of withholding taxes related to net share settlement of exercised options

(989

)

—

Net cash provided by financing activities

198,180

2,392

Net change in cash

143,193

(29,478

)

Foreign exchange differences

(2,496

)

3,062

Cash at the beginning of the period

340,450

467,728

Cash at the end of the period

481,147

441,312

Noncash financing and investing activities

Receivable related to exercise of warrants

1,271

—

 

 EX-101.SCH 3 nams-20240509.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Trading Symbol Trading Symbol Soliciting Material Soliciting Material Entity Address City Or Town Entity Address City Or Town Written Communications Written Communications Class of Stock [Domain] Class of Stock [Domain] Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Class of Stock [Axis] Class of Stock [Axis] Entity Ex Transition Period Entity Ex Transition Period Document Period End Date Document Period End Date Document And Entity Information [Line Items] Document And Entity Information [Line Items] Entity Address Postal Zip Code Entity Address Postal Zip Code Entity Incorporation State Country Code Entity Incorporation State Country Code Local Phone Number Local Phone Number Country Region Country Region City Area Code City Area Code Warrant [Member] Warrant [Member] Common Stock [Member] Common Stock [Member] Pre Commencement Tender Offer Pre Commencement Tender Offer Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Entity File Number Entity File Number Entity Address Address Line 1 Entity Address Address Line 1 Security 12b Title Security 12b Title Entity Address Country Entity Address Country Document Type Document Type Document And Entity Information [Table] Document And Entity Information [Table] XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
May 09, 2024
Document And Entity Information [Line Items]  
Document Type 8-K
Document Period End Date May 09, 2024
Entity Registrant Name NewAmsterdam Pharma Company N.V.
Entity Incorporation State Country Code P7
Entity File Number 001-41562
Entity Tax Identification Number 00-0000000
Entity Address Address Line 1 Goomieer 2-35
Entity Address City Or Town Naarden
Entity Address Country NL
Entity Address Postal Zip Code 1411 DC
Country Region 31 (0)
City Area Code 35
Local Phone Number 206 2971
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Amendment Flag false
Entity Central Index Key 0001936258
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Ordinary shares, nominal value €0.12 per share
Trading Symbol NAMS
Security Exchange Name NASDAQ
Warrant [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Warrants to purchase ordinary shares
Trading Symbol NAMSW
Security Exchange Name NASDAQ
EXCEL 6 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 3 24 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports nams-20240509.htm nams-20240509.xsd http://xbrl.sec.gov/dei/2023 false false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nams-20240509.htm": { "nsprefix": "nams", "nsuri": "http://www.newamsterdampharma.com/20240509", "dts": { "inline": { "local": [ "nams-20240509.htm" ] }, "schema": { "local": [ "nams-20240509.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 2, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 31, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 27 }, "report": { "R1": { "role": "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_e1f24dcd-8ab5-4d9f-ad3a-44de2368b4a3", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "nams-20240509.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e1f24dcd-8ab5-4d9f-ad3a-44de2368b4a3", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "nams-20240509.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Country Region", "terseLabel": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "nams_DocumentAndEntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.newamsterdampharma.com/20240509", "localname": "DocumentAndEntityInformationLineItems", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "auth_ref": [] }, "nams_DocumentAndEntityInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.newamsterdampharma.com/20240509", "localname": "DocumentAndEntityInformationTable", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "terseLabel": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "terseLabel": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Country", "terseLabel": "Entity Address Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrant [Member]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.newamsterdampharma.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0000950170-24-056292-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-056292-xbrl.zip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nams-20240509_htm.xml IDEA: XBRL DOCUMENT 0001936258 us-gaap:CommonStockMember 2024-05-09 2024-05-09 0001936258 2024-05-09 2024-05-09 0001936258 us-gaap:WarrantMember 2024-05-09 2024-05-09 false 0001936258 00-0000000 8-K 2024-05-09 NewAmsterdam Pharma Company N.V. P7 001-41562 Goomieer 2-35 Naarden NL 1411 DC 31 (0) 35 206 2971 false false false false Ordinary shares, nominal value €0.12 per share NAMS NASDAQ Warrants to purchase ordinary shares NAMSW NASDAQ true false